



## ASX RELEASE

### Withdrawal of S-1

**EMERYVILLE, California and BRISBANE, Australia, 10 June 2008: Peplin, Inc.** (ASX:PLI) today announced that it had withdrawn its registration statement on Form S-1 and will pursue alternative financing options.

**Further information:**

Michael Aldridge  
Chief Executive Officer  
Tel: +1-510-653 9700  
[michael.aldridge@peplin.com](mailto:michael.aldridge@peplin.com)

**ABOUT PEPLIN**

Peplin is a development stage specialty pharmaceutical company focused on advancing and commercializing innovative medical dermatology products. Peplin is currently developing PEP005 (ingenol mebutate), which is the first in a new class of compounds and which is derived from the sap of *Euphorbia peplus*, or *E. peplus*, a rapidly growing, readily available plant commonly referred to as petty spurge or radium weed. *E. peplus* has a long history of traditional use for a variety of conditions, including the topical self-treatment of various skin disorders, including skin cancer and pre-cancerous skin lesions. Peplin's lead product candidate is a patient-applied topical gel containing ingenol mebutate, a compound the use of which Peplin has patented for the treatment of actinic keratosis, or AK. This product candidate is currently in Phase II clinical trials and is referred to as PEP005 (ingenol mebutate) Gel.

**PEPLIN, INC.**

6475 Christie Avenue, Emeryville, CA 94608, USA  
Tel: +1-510-653 9700 Fax: +1-510-653 9704

Level 2, Brisbane Portal, 1 Breakfast Creek Road, Newstead, QLD, 4006, Australia  
Tel: +61-7-3250 1200 Fax: +61-7-3250 1299

[www.peplin.com](http://www.peplin.com)